The genetic architecture of multiple myeloma.
Gareth J Morgan, Brian A Walker, Faith E Davies
https://pubmed.ncbi.nlm.nih.gov/22495321/Actively Recruiting
Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2026-04-23
60
Participants Needed
4
Research Sites
72 weeks
Total Duration
Researchers are studying monoclonal gammopathy of undetermined significance MGUS, smoldering multiple myeloma SMM, and multiple myeloma MM to identify molecular and immune markers linked to disease progression. This observational study integrates genomic, transcriptomic, immunophenotypic, and oral microbiome analyses to better understand how these conditions evolve into symptomatic MM. The study also includes in vitro experiments to explore bone damage and immune system dysfunction, aiming to improve early risk assessment and support future preventive treatments. Participants include patients with MGUS, SMM, or MM, as well as healthy volunteers undergoing joint replacement surgery for osteoarthritis who serve as controls. Biological samples such as bone marrow aspirates, biopsies, peripheral blood, and gingival crevicular fluid are collected during routine care or surgery. The study follows patients up to 24 months, analyzing their immune cells, genetic profiles, and oral microbiome to unravel disease mechanisms and progression markers. Participants will undergo several assessments including immunophenotypic characterization of bone marrow and blood, genomic and transcriptomic profiling of plasma cells, and single-cell and spatial transcriptomic analyses. Oral microbiome composition will also be evaluated. Researchers will validate genetic profiles related to bone disease using functional studies. The study involves routine collection of leftover clinical samples and non-invasive fluid samples, with all procedures designed to understand disease biology and improve future risk prediction over a two-year period.
CONDITIONS
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
N
Noemi Puccio
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda USL Reggio Emilia - IRCCS
Lead Sponsor
European Union
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants provide biological samples including bone marrow aspirate, bone marrow biopsy, peripheral blood, and gingival crevicular fluid. For healthy volunteers, bone tissue is collected during orthopedic surgery and peripheral blood is collected for research.
Samples collected during routine diagnostic procedures and clinical care; additional non-invasive sample collection may occur
Duration - Up to 24 months
Participants are observed over time with ongoing collection of biological samples and immunophenotypic, genomic, and transcriptomic analyses to study disease progression and oral microbiome composition.
Periodic assessments depending on clinical management
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gareth J Morgan, Brian A Walker, Faith E Davies
https://pubmed.ncbi.nlm.nih.gov/22495321/Patrizia Leone, Antonio Giovanni Solimando, Eleonora Malerba...
https://pubmed.ncbi.nlm.nih.gov/33194767/Antonio Palumbo, Kenneth Anderson
https://pubmed.ncbi.nlm.nih.gov/21410373/Sebastien Robiou du Pont, Alice Cleynen, Charlotte Fontan...
https://pubmed.ncbi.nlm.nih.gov/28297630/Bachisio Ziccheddu, Matteo C Da Vià, Marta Lionetti...
https://pubmed.ncbi.nlm.nih.gov/34526359/Niccolò Bolli, Francesco Maura, Stephane Minvielle...
https://pubmed.ncbi.nlm.nih.gov/30135448/Marco Rossi, Emanuela Altomare, Cirino Botta...
https://pubmed.ncbi.nlm.nih.gov/32632096/Azienda USL Reggio Emilia - IRCCS
Lead Sponsor
European Union
Collaborating Sponsor